A Phase I/II Study of the Pharmacokinetics, Tolerability and Safety of Administration of VX-853 [timcodar] to Patients Receiving Single Agent Therapy With Doxorubicin HCI

Trial Profile

A Phase I/II Study of the Pharmacokinetics, Tolerability and Safety of Administration of VX-853 [timcodar] to Patients Receiving Single Agent Therapy With Doxorubicin HCI

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Timcodar (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 20 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top